RIGL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Rigel Pharmaceuticals Inc (RIGL) is not a strong buy at the moment for a beginner investor with a long-term focus. While the company has shown strong financial performance in its latest quarter, the lack of significant positive catalysts, neutral trading sentiment, and recent negative news regarding its collaboration termination with Eli Lilly suggest caution. Additionally, technical indicators do not show a strong bullish trend, and there are no proprietary trading signals to support an immediate buy decision.
The MACD is positive but contracting, RSI is neutral at 48.004, and moving averages are converging. The stock is trading near its pivot level of 31.075 with support at 29.397 and resistance at 32.753. No strong bullish or bearish signals are present.
The company's financial performance in Q4 2025 was strong, with significant YoY growth in revenue, net income, EPS, and gross margin.
Eli Lilly's termination of its collaboration agreement with Rigel Pharmaceuticals raises concerns about future revenue streams. Additionally, the company is experiencing a decline in contract revenue, which could impact its financial stability.
In Q4 2025, Rigel Pharmaceuticals reported a 21.19% YoY increase in revenue, a 1769.22% YoY increase in net income, a 1557.50% YoY increase in EPS, and a 1.69% YoY increase in gross margin to 91.47%.
No recent analyst rating or price target changes are available for evaluation.
